Immune response evaluation criteria in solid tumors for assessment of atypical responses after immunotherapy

Table 1 Incidence of atypical response in different cancer types and treatments, according to the most recent literature

Response	Cancer type	Treatment	Incidence (% range)
Pseudoprogression	Melanoma	Ipilimumab	7.4-9.7
		Tremelimumab	2.8-6.3
		PD1/PD-L1 inhibitors	3.7-8.3
		Pembrolizumab	3.7-7.3
	RCC	PD1/PD-L1 inhibitors	4.9-14.8
		Atezolizumab	2.9
	NSCLC	PD1/PD-L1 inhibitors	1.9-6.9
		Atezolizumab	2.8
	Urothelial	Atezolizumab	1.5-6.8
		Durvalumab	7.1
		PD1/PD-L1 inhibitors	8.9
	HNSCC	Pembrolizumab	1.8
		PD1/PD-L1 inhibitors	1.3
	Mesothelioma	Tremelimumab	6.9
Hyperprogression	NSCLC	PD1/PD-L1 inhibitors	8.0-14.0
	Gastric	PD1/PD-L1 inhibitors	21.0-29.4
	RCC	PD1/PD-L1 inhibitors	7.0-46.0
	Melanoma	PD1/PD-L1 inhibitors	1.2
Dissociated response	NSCLC	PD1/PD-L1 inhibitors	7-5-10

HNSCC: Head and neck squamous cell carcinoma; NSCLC: Non-small lung cell carcinoma; PD1: Programmed cell death 1; PD-L1: Programmed death-ligand 1; RCC: Renal cell carcinoma.